Research Landing

Heart failure

RED-HF
A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of Darbepoetin alfa treatment on mortality and morbidity in heart failure (HF) subjects with symptomatic left ventricular systolic dysfunction and anemia

Inclusion criteria

  • Patients with CHF for >3 months and NYHA class II, III, or IV
  • EF <40%
  • Hemoglobin must be between 9.0 g/dL-12.0 g/dL
  • Exclusion criteria
  • B12 or Folate below lower limit of normal
  • Tsat is <15%
  • CHF is primarily due to valvular disease

Principal investigator: Alicia Ross, M.D.
Sponsor: Amgen Pharmaceuticals
Contact: Michelle Dixon, CCRC, clinical research coordinator, 503-215-6746

TOPCAT
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist

Inclusion criteria

  • Patients with CHF (new or previous)
  • EF >45%
  • BNP >100 pg/ml OR hospitalized in last 12 months with CHF
  • Exclusion criteria
  • Serum Potassium >5.0 mmol/L
  • MI in past 90 days
  • Significant chronic pulmonary disease
Principal investigator: Alicia Ross, M.D.
Sponsor: National Heart, Lung and Blood Institute, part of the NIH
Contact: Michelle Dixon, CCRC, clinical research coordinator, or 503-215-6746